Business Context and Reporting Period
CareDx, Inc. (CDNA) filed a Form 8-K on June 10, 2020, reporting the entry into a material definitive agreement for an underwritten public offering of common stock. The company is incorporated in Delaware and its principal executive offices are located in South San Francisco, California.
Key Financial Metrics and Transaction Details
- Shares Offered: 3,906,250 shares of Common Stock.
- Public Offering Price: $32.00 per share.
- Underwriting Price: $30.08 per share.
- Expected Net Proceeds: Approximately $117.1 million (excluding the option to purchase additional shares).
- Over-Allotment Option: Underwriters granted an option to purchase up to 585,937 additional shares at the public offering price, exercisable for 30 days.
- Expected Closing Date: On or about June 15, 2020.
Material Changes and Agreements
The primary material change is the execution of an Underwriting Agreement with Goldman Sachs & Co. LLC and Jefferies LLC as joint book-running managers. This agreement facilitates the capital raise described above. Additionally, the company's directors and executive officers have entered into "lock-up" agreements prohibiting the sale or transfer of company securities until September 9, 2020, with limited exceptions for Rule 10b5-1 trading plans.
Guidance, Risks, and Contingencies
The filing contains forward-looking statements regarding the anticipated closing of the offering and the amount of proceeds. Management cautions that these statements are subject to risks and uncertainties, including the ability to satisfy closing conditions, market conditions, and other risks detailed in periodic reports. The company does not intend to update these forward-looking statements except as required by law. The filing does not provide specific operational guidance or revenue forecasts beyond the transaction details.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received after deducting all expenses.
- Confirm whether the underwriters exercised the over-allotment option to purchase the additional 585,937 shares.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants and indemnification terms.
- Monitor the company's use of proceeds as disclosed in subsequent periodic reports.